Biorefineries outlines the processes and steps to successfully scale up production of two types of biofuels, butanol and ethanol, from cellulosic residues for commercial purposes. It covers practical topics, including biomass availability, pretreatment, fermentation, and water recycling, as well as policy and economic factors. This reflects the unique expertise of the editor team, whose backgrounds range from wood and herbaceous feedstocks to process economics and industrial expertise. The strategies presented in this book help readers to design integrated and efficient processes to reduce the cost of production and achieve an economically viable end product
- Outlines the economic benefits of designing a single operational process.
- Includes all currently available processes on pretreatment, fermentation and recovery
- Covers all pretreatment, fermentation, and product recovery options
- Focuses on biofuels but acts as a stepping stone to develop cost-efficient processes for an array of commodity chemicals
Research Chemical/Biochemical Engineer, United States Department of Agriculture (USDA), Agricultural Research Service (ARS), National Center for Agricultural Utilization Research (NCAUR), Peoria, IL, USA.
PhD (Chemical/Biological Engineering), PhD (Fermentation Technology)
Fellow in American Institute of Chemical Engineers (AIChE), Society for Industrial Microbiology & Biotechnology (SIMB), and American Institute of Chemists (AIC).
Co-Editor, Stem cells in Regenerative Medicine (Wiley, 2015)
Michigan State University, MI USA
University of Illinois at Urbana-Champaign, Institut Pasteur Paris, and University of Lille Flanders-Artois
• Sloan Fellow from London Business School and a microbiologist by training (University of Illinois at Urbana-Champaign, Institut Pasteur Paris, and University of Lille Flandres-Artois).
• Consulting, Partnering & Fund Raising, Founder, Managing Director, NxR Biotechnologies, Switzerland.
• Dr. Vertès is a strategy and business development consultant for cell therapeutic biotech companies, and works to enable seed funding in the field. Focusing on technology deployment and innovation commercialization, he has contributed to both industrial and pharmaceutical biotechnology, in different functions including research, manufacturing, contract research, and strategic alliances in pharmaceuticals (Lilly, Pfizer, Roche).
• Championed radical innovation for bringing to patients disease-modifying, paradigm-changing therapeutics such as siRNA, and led in a scientific and business manner Roche’s global cell therapeutics strategy and implementation team resulting in Roche’s entry in 2010 in the field of regenerative medicine.
• Member, Industry Committee-Europe, Tissue Engineering and Regenerative Medicine International Society
• Co-Editor, Stem Cells in Regenerative Medicine: Science, Regulation and Business Strategies (Wiley, 2015).
